Johnson & Johnson is expanding its ambitious project to learn how to predict who will develop particular diseases and find therapies to prevent or stop disease early on. That's when it's most treatable.
The health care giant announced its groundbreaking project in February 2015. It now includes 24 research programs with partners in government, universities and other drug and diagnostic test companies. Their expertise and resources should speed discoveries.
J&J is announcing the latest two projects. They're meant to identify which pregnant women will develop gestational diabetes, and to identify and treat people at risk of or in early stages of chronic obstructive pulmonary disease.
The J&J project head, Ben Wiegand, tells The Associated Press that the researchers are moving from disease care to health care.